Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Randomized Experiments01:13

Randomized Experiments

6.7K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
6.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

83
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
83
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

140
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
140
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

82
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
82
Blinding01:11

Blinding

2.4K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiviral Potential of Selenium-Enriched Bacillus pumilus: Inhibition of PCV2 Replication via Alleviation of Oxidative Stress.

Journal of applied microbiology·2026
Same author

Delphi survey to explore core curriculum for training the next-generation of hepatologists<sup>☆</sup>.

JHEP reports : innovation in hepatology·2026
Same author

Exon junction complex and nuclear pore complex components preferentially govern the nuclear export of spliced lncRNAs.

Cell death discovery·2026
Same author

Biocompatible and long-acting polyphosphate inhibitors for the diagnosis and treatment of thrombosis and thromboembolism.

Biomaterials advances·2026
Same author

[<i>Shengqing Jiangzhuo</i> acupuncture method for sepsis-associated gastrointestinal dysfunction: a randomized controlled trial].

Zhongguo zhen jiu = Chinese acupuncture & moxibustion·2026
Same author

Differentiation defects reposition sebaceous glands as inflammatory instigators in the early pathogenesis of hidradenitis suppurativa.

Frontiers in immunology·2026

Related Experiment Video

Updated: May 31, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K

Matching-Assisted Power Prior for Incorporating Real-World Data in Randomized Clinical Trial Analysis.

Ruoyuan Qian1, Biqing Yang2, Xinyi Xu2

  • 1Division of Biostatistics, College of Public Health, The Ohio State University, Ohio, USA.

Statistics in Medicine
|January 23, 2025
PubMed
Summary

This study introduces a novel matching-assisted power prior method to improve the use of external data in clinical trials, especially for rare diseases. This approach enhances statistical power by selecting comparable historical controls, leading to more reliable trial results.

Keywords:
Bayesian borrowingpower priorpropensity scorereal‐world datatemplate matching

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K

Related Experiment Videos

Last Updated: May 31, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Real-World Data Analysis

Background:

  • Randomized clinical trials (RCTs) face challenges in rare diseases due to recruitment difficulties.
  • External data, particularly from historical trials, offers a potential solution to augment limited trial data.
  • Existing methods for incorporating external data, like Bayesian power priors and propensity score adjustments, have limitations in mitigating bias.

Purpose of the Study:

  • To propose a novel matching-assisted power prior approach for incorporating external data into clinical trials.
  • To enhance statistical power and mitigate bias by improving the selection and weighting of external control subjects.
  • To provide a statistically principled method for leveraging real-world data in hybrid trial designs.

Main Methods:

  • A matching-assisted power prior method is developed, utilizing template matching to select comparable external subjects in groups.
  • Weights are assigned to external subject groups based on their similarity to the current study population.
  • Power priors are employed within a Bayesian inference framework to integrate the weighted external data.

Main Results:

  • The proposed matching-assisted power prior approach demonstrated improved bias mitigation compared to conventional methods.
  • Simulation studies indicated enhanced performance in incorporating external data by pre-selecting high-quality controls.
  • The method was illustrated using data from a real-world acupuncture clinical trial.

Conclusions:

  • The matching-assisted power prior method offers a statistically sound and effective way to leverage external data in clinical trials.
  • This approach is particularly beneficial for rare disease research where patient recruitment is challenging.
  • The method improves the quality of borrowed external data, leading to more robust trial outcomes.